{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:07:03Z","timestamp":1756382823199},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T00:00:00Z","timestamp":1391126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s11894-014-0371-7","type":"journal-article","created":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T03:19:26Z","timestamp":1391051966000},"source":"Crossref","is-referenced-by-count":17,"title":["Acute Hepatitis C: Management in the Rapidly Evolving World of HCV"],"prefix":"10.1007","volume":"16","author":[{"given":"Suraj A.","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,31]]},"reference":[{"key":"371_CR1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333\u201342.","journal-title":"Hepatology"},{"key":"371_CR2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2893.2011.01576.x","volume":"19","author":"J Guerra","year":"2012","unstructured":"Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat. 2012;19:560\u20137.","journal-title":"J Viral Hepat"},{"key":"371_CR3","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(99)06527-7","volume":"355","author":"C Frank","year":"2000","unstructured":"Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355:887\u201391.","journal-title":"Lancet"},{"key":"371_CR4","doi-asserted-by":"crossref","first-page":"14757","DOI":"10.1073\/pnas.1008877107","volume":"107","author":"FD Miller","year":"2010","unstructured":"Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci USA. 2010;107:14757\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 2","key":"371_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","volume":"31","author":"W Sievert","year":"2011","unstructured":"Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31 Suppl 2:61\u201380.","journal-title":"Liver Int"},{"key":"371_CR6","first-page":"545","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","unstructured":"Centers for Disease Control and Prevention (CDC). Progress toward prevention and control of hepatitis C virus infection--Egypt, 2001-2012. MMWR. 2012;61:545\u20139.","journal-title":"MMWR"},{"key":"371_CR7","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1136\/gut.2009.194266","volume":"59","author":"A Paez Jimenez","year":"2010","unstructured":"Paez Jimenez A, Sharaf Eldin N, Rimlinger F, El-Daly M, El-Hariri H, El-Hoseiny M, et al. HCV iatrogenic and intrafamilial transmission in Greater Cairo. Egypt Gut. 2010;59:1554\u201360.","journal-title":"Egypt Gut"},{"key":"371_CR8","doi-asserted-by":"crossref","first-page":"e8467","DOI":"10.1371\/journal.pone.0008467","volume":"4","author":"J Lu","year":"2009","unstructured":"Lu J, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, et al. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS ONE. 2009;4:e8467.","journal-title":"PLoS ONE"},{"key":"371_CR9","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.3748\/wjg.15.5647","volume":"15","author":"Y Waheed","year":"2009","unstructured":"Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. WJG. 2009;15:5647\u201353.","journal-title":"WJG"},{"key":"371_CR10","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3201\/eid1511.090263","volume":"15","author":"F Liu","year":"2009","unstructured":"Liu F, Chen K, He Z, Ning T, Pan Y, Cai H, et al. Hepatitis C seroprevalence and associated risk factors, Anyang, China. Emerg Infect Dis. 2009;15:1819\u201322.","journal-title":"Emerg Infect Dis"},{"key":"371_CR11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2007.07.033","volume":"48","author":"JI Esteban","year":"2008","unstructured":"Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008;48:148\u201362.","journal-title":"J Hepatol"},{"key":"371_CR12","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1080\/00365520310004542","volume":"38","author":"O Dalgard","year":"2003","unstructured":"Dalgard O, Jeansson S, Skaug K, Raknerud N, Bell H. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol. 2003;38:864\u201370.","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl 1","key":"371_CR13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0168-8278(99)80380-8","volume":"31","author":"NV Naoumov","year":"1999","unstructured":"Naoumov NV. Hepatitis C, virus infection in Eastern Europe. J Hepatol. 1999;31 Suppl 1:84\u20137.","journal-title":"J Hepatol"},{"key":"371_CR14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jmv.2066","volume":"65","author":"O Kalinina","year":"2001","unstructured":"Kalinina O, Norder H, Vetrov T, Zhdanov K, Barzunova M, Plotnikova V, et al. Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use. J Med Virol. 2001;65:517\u201324.","journal-title":"J Med Virol"},{"key":"371_CR15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2458-9-34","volume":"9","author":"N M\u00fchlberger","year":"2009","unstructured":"M\u00fchlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009;9:34.","journal-title":"BMC Public Health"},{"key":"371_CR16","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/BF01718286","volume":"141","author":"DK Lvov","year":"1996","unstructured":"Lvov DK, Samokhvalov EI, Tsuda F, Selivanov NA, Okamoto H, Stakhanova VM, et al. Prevalence of hepatitis C virus and distribution of its genotypes in Northern Eurasia. Arch Virol. 1996;141:1613\u201322.","journal-title":"Arch Virol"},{"key":"371_CR17","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1478-3231.2011.02494.x","volume":"31","author":"E Chak","year":"2011","unstructured":"Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090\u2013101.","journal-title":"Liver Int"},{"key":"371_CR18","first-page":"1","volume":"61","author":"BD Smith","year":"2012","unstructured":"Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo C-G, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61:1\u201332.","journal-title":"MMWR Recomm Rep"},{"key":"371_CR19","unstructured":"phac-aspc.gc.ca [Internet]. [cited 2013 Sep 28]. Available from: http:\/\/www.phac-aspc.gc.ca ."},{"key":"371_CR20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archinternmed.2010.511","volume":"171","author":"IT Williams","year":"2011","unstructured":"Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med. 2011;171:242\u20138.","journal-title":"Arch Intern Med"},{"key":"371_CR21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3851\/IMP2459","volume":"17","author":"S Selvarajah","year":"2012","unstructured":"Selvarajah S, Busch MP. Transfusion transmission of HCV, a long but successful road map to safety. Antivir Ther (Lond). 2012;17:1423\u20139.","journal-title":"Antivir Ther (Lond)"},{"key":"371_CR22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1086\/653937","volume":"51","author":"GE Fischer","year":"2010","unstructured":"Fischer GE, Schaefer MK, Labus BJ, Sands L, Rowley P, Azzam IA, et al. Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008. Clin Infect Dis. 2010;51:267\u201373.","journal-title":"Clin Infect Dis"},{"key":"371_CR23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/jhep.2001.22112","volume":"33","author":"JR Orland","year":"2001","unstructured":"Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology. 2001;33:321\u20137.","journal-title":"Hepatology"},{"key":"371_CR24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJM199107113250205","volume":"325","author":"P Farci","year":"1991","unstructured":"Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med. 1991;325:98\u2013104.","journal-title":"N Engl J Med"},{"key":"371_CR25","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1537-2995.2005.04390.x","volume":"45","author":"SA Glynn","year":"2005","unstructured":"Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion. 2005;45:994\u20131002.","journal-title":"Transfusion"},{"key":"371_CR26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/hep.20742","volume":"42","author":"JW Mosley","year":"2005","unstructured":"Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, et al. Viral and host factors in early hepatitis C virus infection. Hepatology. 2005;42:86\u201392.","journal-title":"Hepatology"},{"key":"371_CR27","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cyto.2012.06.015","volume":"59","author":"Z Makowska","year":"2012","unstructured":"Makowska Z, Heim MH. Interferon signaling in the liver during hepatitis C virus infection. Cytokine. 2012;59:460\u20136.","journal-title":"Cytokine"},{"key":"371_CR28","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.194.10.1395","volume":"194","author":"R Thimme","year":"2001","unstructured":"Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194:1395\u2013406.","journal-title":"J Exp Med"},{"key":"371_CR29","doi-asserted-by":"crossref","unstructured":"Seeff LB. Natural history of hepatitis C. 1997. p. 21S\u20138S.","DOI":"10.1002\/hep.510260704"},{"key":"371_CR30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2036.2010.04549.x","volume":"33","author":"R Loomba","year":"2011","unstructured":"Loomba R, Rivera MM, McBurney R, Park Y, Haynes-Williams V, Rehermann B, et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther. 2011;33:559\u201365.","journal-title":"Aliment Pharmacol Ther"},{"key":"371_CR31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bpg.2012.09.009","volume":"26","author":"B Maasoumy","year":"2012","unstructured":"Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26:401\u201312.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"371_CR32","first-page":"80","volume":"125","author":"JT Gerlach","year":"2003","unstructured":"Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung M-C, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. YGAST. 2003;125:80\u20138.","journal-title":"YGAST"},{"key":"371_CR33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJM199608293350904","volume":"335","author":"P Farci","year":"1996","unstructured":"Farci P, Alter HJ, Shimoda A, Govindarajan S, Cheung LC, Melpolder JC, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med. 1996;335:631\u20134.","journal-title":"N Engl J Med"},{"key":"371_CR34","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2012.07.007","volume":"57","author":"B Hajarizadeh","year":"2012","unstructured":"Hajarizadeh B, Grebely J, Dore GJ. Case definitions for acute hepatitis C virus infection: a systematic review. J Hepatol. 2012;57:1349\u201360.","journal-title":"J Hepatol"},{"key":"371_CR35","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1086\/605561","volume":"49","author":"BH McGovern","year":"2009","unstructured":"McGovern BH, Birch CE, Bowen MJ, Reyor LL, Nagami EH, Chung RT, et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis. 2009;49:1051\u201360.","journal-title":"Clin Infect Dis"},{"key":"371_CR36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2893.1996.tb00084.x","volume":"3","author":"TT Nguyen","year":"1996","unstructured":"Nguyen TT, Sedghi-Vaziri A, Wilkes LB, Mondala T, Pockros PJ, Lindsay KL, et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat. 1996;3:75\u20138.","journal-title":"J Viral Hepat"},{"key":"371_CR37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/hep.510310133","volume":"31","author":"L Fanning","year":"2000","unstructured":"Fanning L, Kenny-Walsh E, Levis J, Choudhury KR, Cannon B, Sheehan M, et al. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. Hepatology. 2000;31:225\u20139.","journal-title":"Hepatology"},{"key":"371_CR38","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/hep.510280634","volume":"28","author":"SC Gordon","year":"1998","unstructured":"Gordon SC, Dailey PJ, Silverman AL, Khan BA, Kodali VP, Wilber JC. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology. 1998;28:1702\u20136.","journal-title":"Hepatology"},{"key":"371_CR39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","volume":"13","author":"JM Micallef","year":"2006","unstructured":"Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34\u201341.","journal-title":"J Viral Hepat"},{"key":"371_CR40","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/hep.510290311","volume":"29","author":"SA Villano","year":"1999","unstructured":"Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908\u201314.","journal-title":"Hepatology"},{"key":"371_CR41","unstructured":"Grebely J, Page K, Sacks-Davis R, Schim van der Loeff M, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C Virus infection. Hepatology. 2014;59(1):109\u201320. This study uses a large international cohort of patients with acute HCV to identify predictors of spontaneous clearance, showing that IL28B, HCV genotype and gender were predictive factors."},{"key":"371_CR42","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1086\/522608","volume":"196","author":"CC Wang","year":"2007","unstructured":"Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196:1474\u201382.","journal-title":"J Infect Dis"},{"key":"371_CR43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2893.2011.01497.x","volume":"19","author":"H-Y Rao","year":"2012","unstructured":"Rao H-Y, Sun D-G, Jiang D, Yang R-F, Guo F, Wang J-H, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat. 2012;19:173\u201381.","journal-title":"J Viral Hepat"},{"key":"371_CR44","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1136\/gut.2003.037788","volume":"53","author":"E Spada","year":"2004","unstructured":"Spada E, Mele A, Berton A, Ruggeri L, Ferrigno L, Garbuglia AR, et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut. 2004;53:1673\u201381.","journal-title":"Gut"},{"key":"371_CR45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jhep.2013.04.007","volume":"59","author":"A Mangia","year":"2013","unstructured":"Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, et al. Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. J Hepatol. 2013;59:221\u20138.","journal-title":"J Hepatol"},{"key":"371_CR46","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/hep.23850","volume":"52","author":"J Grebely","year":"2010","unstructured":"Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52:1216\u201324.","journal-title":"Hepatology"},{"issue":"5","key":"371_CR47","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jhep.2013.06.028","volume":"59","author":"S Beinhardt","year":"2013","unstructured":"Beinhardt S, Payer BA, Datz C, Strasser M, Maieron A, Dorn L, et al. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection. J Hepatol. 2013;59(5):972\u20137. This study uses a cohort of 136 patients with acute HCV to identify predictors of spontaneous clearance and then to develop a score to predict spontaneous clearance. Once validated, this could be a useful tool for practitioners.","journal-title":"J Hepatol"},{"key":"371_CR48","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2010.07.005","volume":"139","author":"HL Tillmann","year":"2010","unstructured":"Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010;139:1586\u201392. 1592.e1.","journal-title":"Gastroenterology"},{"key":"371_CR49","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798\u2013801.","journal-title":"Nature"},{"key":"371_CR50","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/hep.26263","volume":"57","author":"J Grebely","year":"2013","unstructured":"Grebely J, Feld JJ, Applegate T, Matthews GV, Hellard M, Sherker A, et al. Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology. 2013;57:2124\u201334. IP-10 levels may provide an additional means of risk stratification. Patients with high IP-10 levels were shown to have a lower likelihood of spontaneous clearance, allowing for early identification of patients who merit treatment.","journal-title":"Hepatology"},{"key":"371_CR51","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3851\/IMP1913","volume":"16","author":"A Mangia","year":"2011","unstructured":"Mangia A, Santoro R, Sarli R, Mottola L, Piazzolla V, Petruzzellis D, et al. IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients. Antivir Ther (Lond). 2011;16:1309\u201316.","journal-title":"Antivir Ther (Lond)"},{"key":"371_CR52","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1053\/j.gastro.2012.10.034","volume":"144","author":"S Zhang","year":"2013","unstructured":"Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon-\u03bb and amplify interferon-\u03b1 in response to hepatitis C virus infection. Gastroenterology. 2013;144:414\u2013425.e7.","journal-title":"Gastroenterology"},{"key":"371_CR53","first-page":"1887","volume":"131","author":"T Marcello","year":"2006","unstructured":"Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. YGAST. 2006;131:1887\u201398.","journal-title":"YGAST"},{"key":"371_CR54","doi-asserted-by":"crossref","unstructured":"Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, et al. Association of the IFNL4-\u0394G Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. J Infect Dis 2014;209(3):350\u20134.","DOI":"10.1093\/infdis\/jit433"},{"key":"371_CR55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","volume":"45","author":"L Prokunina-Olsson","year":"2013","unstructured":"Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45:164\u201371.","journal-title":"Nat Genet"},{"key":"371_CR56","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1086\/507307","volume":"194","author":"AI Romero","year":"2006","unstructured":"Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky J-M, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis. 2006;194:895\u2013903.","journal-title":"J Infect Dis"},{"key":"371_CR57","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/hep.21407","volume":"44","author":"M Lagging","year":"2006","unstructured":"Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky J-M, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. 2006;44:1617\u201325.","journal-title":"Hepatology"},{"key":"371_CR58","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1053\/j.gastro.2012.05.044","volume":"143","author":"MT Dill","year":"2012","unstructured":"Dill MT, Makowska Z, Duong FHT, Merkofer F, Filipowicz M, Baumert TF, et al. Interferon-\u03b3-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology. 2012;143:777\u201386.e1\u20136.","journal-title":"Gastroenterology"},{"key":"371_CR59","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1053\/j.gastro.2011.12.055","volume":"142","author":"E Thomas","year":"2012","unstructured":"Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2012;142:978\u201388.","journal-title":"Gastroenterology"},{"key":"371_CR60","doi-asserted-by":"crossref","unstructured":"Feld JJ, Grebely J, Matthews GV, Applegate T, Hellard M, Sherker A, et al. Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection. PLoS One. 2013;8(11):e80003. doi: 10.1371\/journal.pone.0080003 .","DOI":"10.1371\/journal.pone.0080003"},{"key":"371_CR61","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/hep.23477","volume":"51","author":"S Knapp","year":"2010","unstructured":"Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology. 2010;51:1168\u201375.","journal-title":"Hepatology"},{"key":"371_CR62","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1126\/science.1097670","volume":"305","author":"SI Khakoo","year":"2004","unstructured":"Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305:872\u20134.","journal-title":"Science"},{"key":"371_CR63","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1053\/j.gastro.2011.06.069","volume":"141","author":"G Ahlenstiel","year":"2011","unstructured":"Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology. 2011;141:1231\u20139. 1239.e1\u20132.","journal-title":"Gastroenterology"},{"key":"371_CR64","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.gastro.2011.04.005","volume":"141","author":"S Knapp","year":"2011","unstructured":"Knapp S, Warshow U, Ho KMA, Hegazy D, Little A-M, Fowell A, et al. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology. 2011;141:320\u20135. 325.e1\u20132.","journal-title":"Gastroenterology"},{"key":"371_CR65","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1172\/JCI118842","volume":"98","author":"G Missale","year":"1996","unstructured":"Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest. 1996;98:706\u201314.","journal-title":"J Clin Invest"},{"key":"371_CR66","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/hep.510250233","volume":"25","author":"SL Tsai","year":"1997","unstructured":"Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology. 1997;25:449\u201358.","journal-title":"Hepatology"},{"key":"371_CR67","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/75063","volume":"6","author":"A Takaki","year":"2000","unstructured":"Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000;6:578\u201382.","journal-title":"Nat Med"},{"key":"371_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(98)80195-5","volume":"28","author":"C Zavaglia","year":"1998","unstructured":"Zavaglia C, Martinetti M, Silini E, Bottelli R, Daielli C, Asti M, et al. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. J Hepatol. 1998;28:1\u20137.","journal-title":"J Hepatol"},{"key":"371_CR69","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0168-8278(98)80005-6","volume":"29","author":"ME Cramp","year":"1998","unstructured":"Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol. 1998;29:207\u201313.","journal-title":"J Hepatol"},{"key":"371_CR70","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1128\/JVI.73.4.2938-2946.1999","volume":"73","author":"SC Ray","year":"1999","unstructured":"Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol. 1999;73:2938\u201346.","journal-title":"J Virol"},{"key":"371_CR71","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1126\/science.288.5464.339","volume":"288","author":"P Farci","year":"2000","unstructured":"Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 2000;288:339\u201344.","journal-title":"Science"},{"key":"371_CR72","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.3748\/wjg.v11.i19.2874","volume":"11","author":"S Chen","year":"2005","unstructured":"Chen S, Wang Y-M. Multigene tracking of quasispecies in viral persistence and clearance of hepatitis C virus. WJG. 2005;11:2874\u201384.","journal-title":"WJG"},{"key":"371_CR73","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","volume":"345","author":"E Jaeckel","year":"2001","unstructured":"Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345:1452\u20137.","journal-title":"N Engl J Med"},{"key":"371_CR74","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.20196","volume":"39","author":"H Nomura","year":"2004","unstructured":"Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004;39:1213\u20139.","journal-title":"Hepatology"},{"key":"371_CR75","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2004.11.021","volume":"42","author":"T Santantonio","year":"2005","unstructured":"Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005;42:329\u201333.","journal-title":"J Hepatol"},{"key":"371_CR76","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.21043","volume":"43","author":"J Wiegand","year":"2006","unstructured":"Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43:250\u20136.","journal-title":"Hepatology"},{"key":"371_CR77","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2893.2006.00802.x","volume":"14","author":"G Calleri","year":"2007","unstructured":"Calleri G, Cariti G, Gaiottino F, De Rosa FG, Bargiacchi O, Audagnotto S, et al. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat. 2007;14:116\u201321.","journal-title":"J Viral Hepat"},{"key":"371_CR78","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2893.2009.01167.x","volume":"17","author":"KE Corey","year":"2010","unstructured":"Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat. 2010;17:201\u20137.","journal-title":"J Viral Hepat"},{"key":"371_CR79","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/hep.20266","volume":"39","author":"SM Kamal","year":"2004","unstructured":"Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology. 2004;39:1721\u201331.","journal-title":"Hepatology"},{"key":"371_CR80","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/QAD.0b013e3283553719","volume":"26","author":"J Grebely","year":"2012","unstructured":"Grebely J, Hellard M, Applegate T, Petoumenos K, Yeung B, Feld JJ, et al. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV\/HIV co-infection. AIDS. 2012;26:1653\u201361.","journal-title":"AIDS"},{"key":"371_CR81","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","volume":"55","author":"European Association for the Study of the Liver","year":"2011","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245\u201364.","journal-title":"J Hepatol"},{"key":"371_CR82","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1053\/j.gastro.2006.01.034","volume":"130","author":"SM Kamal","year":"2006","unstructured":"Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Tawil Al A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006;130:632\u20138.","journal-title":"Gastroenterology"},{"key":"371_CR83","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.21197","volume":"43","author":"SM Kamal","year":"2006","unstructured":"Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology. 2006;43:923\u201331.","journal-title":"Hepatology"},{"key":"371_CR84","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jhep.2010.10.033","volume":"55","author":"J Grebely","year":"2011","unstructured":"Grebely J, Matthews GV, Hellard M, Shaw D, van Beek I, Petoumenos K, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol. 2011;55:76\u201385.","journal-title":"J Hepatol"},{"key":"371_CR85","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drugalcdep.2007.09.008","volume":"93","author":"J Grebely","year":"2008","unstructured":"Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008;93:141\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"371_CR86","doi-asserted-by":"crossref","unstructured":"Martin TCS, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, et al. HCV reinfection incidence and treatment outcome among HIV-positive MSM in London. AIDS. 2013;27(16):2551\u20137.","DOI":"10.1097\/QAD.0b013e32836381cc"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-014-0371-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-014-0371-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-014-0371-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T21:04:49Z","timestamp":1597439089000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-014-0371-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,31]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["371"],"URL":"https:\/\/doi.org\/10.1007\/s11894-014-0371-7","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,31]]},"article-number":"371"}}